Perspective on the Clinical Management of Recurrent/Metastatic HNSCC – Vancouver
- Overview of the clinical management of unresectable recurrent and metastatic HNSCC.
- Need for evidence-based medicine in a COVID environment and beyond.
- Share US experience and sequencing of available therapies.
Registration is complimentary and restricted to healthcare professionals. Please click the button below to complete the transaction:
About the Faculty
Dr. Cheryl Ho
Bio coming soon!
Dr. Barbara Burtness
Dr.Barbara Burtness is Professor of Medicine at the Yale University School of Medicine. She is co-leader of the Developmental Therapeutics Program, Director of the Head and Neck Clinical Research Programat Yale Cancer Center, and Principal Investigator of the Yale Head and Neck Cancer Specialized Program of Research Excellence. Dr.Burtness’ research focuses on translational studies in head and neck cancer, including biomarkers of resistance to EGFR inhibitionand synthetic lethal approaches for HPV negative head and neck cancer.She chairs the ECOG-ACRIN Head and Neck Cancer Therapeutics Committee, which conducts multicentertrials of novel treatment paradigms to improve the survival and functional outcomes of patients with all stages of head and neck cancers. She has conducted numerous phase I–III investigator-initiated trials,andis coordinating investigator for phase III registration trials of afatinib in the post-radiation setting and pembrolizumab in the first-line setting
This program has been made possible through unrestricted support from Merck.